Trials / Terminated
TerminatedNCT03993379
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- CytomX Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CX-072 | CX-072 in combination with ipilimumab |
| DRUG | Ipilimumab | CX-072 in combination with ipilimumab |
Timeline
- Start date
- 2019-11-20
- Primary completion
- 2020-05-21
- Completion
- 2020-05-21
- First posted
- 2019-06-20
- Last updated
- 2025-12-26
- Results posted
- 2021-12-01
Locations
27 sites across 5 countries: United States, Australia, Netherlands, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03993379. Inclusion in this directory is not an endorsement.